http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이민수,김용구,김영훈,연병길,오병훈,윤도준,윤진상,이철,정희연,강병조,김광수,김동언,김명정,김상훈,김희철,나철,노승호,민경준,박기창,박두병,백기청,백인호,손봉기,손진욱,양병환,양창국,우행원,이정호,이종범,이홍식,임기영,전태연,정영조,정영철,정인과,정인원,지익성,채정호,한상익,한선호,한진희,서광윤 大韓神經精神醫學會 1998 신경정신의학 Vol.37 No.1
연구목적 : 본 시험의 목적은 임상시험 시작전에 연구자들을 대상으로 PANSS Workshop을 통하여 PANSS, ESRS에 대한 국내에서의 표준화 작업을 구축하고 새로운 정신병 치료제인 리스페리돈의 효과와 안정성을 재확인하여 리스페리돈 사용에 대한 적정화를 이루는데 있다. 연구방법 : 1996년 4월부터 1996년 9월까지 국내 39개 대학병원 정신과에 입원중인 혹은 증상이 악화되어 입원하는 정신분열병 환자 377명을 대상으로 다시설 개방 연구를 시행하였다. 1주일간의 약물 배설기간을 가진후, 리스페리돈을 8주간 투여하였고, 기준점, 1주, 2주, 4주, 그리고 8주후에 평가되었다. 용량은 제1일에는 리스페리돈 1mg씩 1일 2회, 제2일에는 2mg씩 1일 2회, 제3∼7일에는 3mg씩 1일 2회 투여하였다. 이후 환자의 임상상태에 따라 임의로 증량할 수 있으며, 최대 일일 16mg을 초과하지 않도록 하였다. 추체외로 증상을 조절하기 위한 투약을 허용하였다. 임상증상 및 부작용의 평가는 PANSS(Positive and Negative Syndrome Scale), CGI(Clinical Global Impression) 그리고 ESRS(Extrapyramidal Symptom Rating Scale)을 사용하였다. 연구결과 : 377명중 343명(91%)이 8주간의 연구를 완결하였다. 치료 종결시점인 8주후 PANSS 총점수가 20% 이상 호전된 경우를 약물 반응군으로 정의할때, 약물반응군은 81.3%였다. 리스페리돈에 반응하는 예측인자로는 발병연령, 이전의 입원 횟수, 유병기간이 관련 있었다. 리스페리돈은 1주후부터 PANSS양성, 음성, 및 일반정신병리 점수상에 유의한 호전을 보여 효과가 빨랐다. CGI의 경우도 기준점에 비해 1주후부터 유의한 감소를 나타내었다. ESRS의 경우, 파킨슨 평가점수는 기준점과 비교해 투여 1주, 2주, 4주후 유의하게 증가되었다가 8주후 기준점과 차이가 없었다. Dystonia 평가점수는 1주후만 유의한 증가를 보였으며, dyskinesia 평가점수는 유의한 차이가 없었다. 혈압, 맥박수의 생명징후 및 일반 혈액학 검사, 생화학적 검사, 심전도 검사에서 유의한 변화는 없었다. 결 론 : 이상의 다시설 개방 임상 연구를 통해 리스페리돈은 정신분열병 환자에서 양성증상뿐만 아니라 음성증상 및 전반적인 증상에도 효과적인 것으로 사료된다. 보다 명확한 평가를 위해서는 다른 항정신병약물과의 이중맹검 연구가 필요할 것으로 생각되며, 또한 장기적 치료에 대한 평가도 함께 이루어져야 하겠다. Objective : The purpose of this study was to investigate the efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method : This multicenter open study included 377 schizophrenic patients drawn from 39 university hospitals. After a wash-out period of 1 week, the schizophrenic patients were treated with risperidone for 8 weeks and evaluated at 5 points ; at baseline, and 1, 2, 4 and 8 weeks of treatment. The dose was increased from 2mg/day(1mg twice daily) to 6mg/day(3mg twice daily) during the first week and adjusted to a maximum of 16mg/day over the next 7 weeks according to the patient's clinical response. Medication to control extrapyramidal symptoms was permitted. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results : 343(91%) of 377 patients completed the 8-week trial period. Clinical improvement, as defined by a 20% or more reduction in total PANSS score at end point, was shown by 81.3% of patients. The predictors of response to risperidone were associated older age, shorter duration of illness, fewer previous hospitalization. Risperidone had rapid onset of action ; a significant decrease of the total PANSS and three PANSS factor(positive, negative, general), and CGI was already noticed at the end of first week. For the ESRS, parkinsonism rating scores were significantly increased until week 4 comparing with baseline. Dystonia rating scores were significantly increased until week 1, and dyskinesia rating scores were not significantly changed during the study. Laboratory parameters including vital sign, EKG, hematological, and biochemical values showed no significant changes during the trial. Conclusions : This study suggests that risperidone is generally safe and effective against both the positive and negative symptoms in our group of patients.
상악동에 발생한 거대한 Cholesterol 육아종 1례
김승찬,박형욱,김용기,나한조,도남용 朝鮮大學校 附設 醫學硏究所 1991 The Medical Journal of Chosun University Vol.16 No.1
The cholesterol granuloma is not a specific clinical or pathologic entity but merely a term used to describe a tissue response to cholesterol crystal. The cholesterol granuloma in paranasal sinuses is rare disease. Recently the authors had experienced a case of huge cholesterol granuloma, which involved the right maxillary sinus. The cholesterol granuloma was removed successfully by mean of enucleation through the Caldwell-Luc approach. So, we report a case with brief review of the literature.
( Young Youn Cho ),( Su Jong Yu ),( Hye Won Lee ),( Do Young Kim ),( Wonseok Kang ),( Yong-han Paik ),( Pil Soo Sung ),( Si Hyun Bae ),( Su Cheol Park ),( Young Seok Doh ),( Kang Mo Kim ),( Eun Sun Ja 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Sorafenib is the standard systemic therapy for treatment of advanced stage hepatocellular carcinoma (HCC), and progressive HCC after locoregional therapy. The efficacy and safety of the drug in clinical practice have been addressed by several real world studies. However, little data are available regarding clinical factors of good responders following sorafenib treatment. This study aimed to evaluate prognostic factors of long term survivors. Methods: This multi-center retrospective cohort study included 1,605 unresectable HCC patients who received sorafenib treatment between 2007 and 2014 in 9 tertiary centers in Korea. The patients were classified into long-term survivor group (survival longer than 2 years, n=246) or control group (n=1,359). The primary endpoint was prognostic factors on survival for overall patients. Secondary endpoints included time-to-progression and other safety profiles. Results: The patients were predominantly male (83.8%), chronic hepatitis B (77.3%), and Barcelona Clinic of Liver Cancer stage C (78.3%). The median overall survival was 9.0 months. After treatment, 12 patients (0.7%) achieved complete response, and 146 patients (9.1%) achieved partial response by mRECIST criteria. The prognostic factors predicting long-term survival were metformin use (hazard ratio [HR]=2.44; P=0.004), hand foot skin reaction (HR=1.77; P=0.001), and concomittent treatment with chemoembolization or radiotherapy (HR =2.59; P<0.001). Prognostic factors against long-term survival were child pugh score B (HR=0.375; P< 0.001), presence of extrahepatic metastasis (HR=0.625; P=0.002), main portal vein invasion (HR=0.625; P=0.002), and elevated AFP ( >1,000 ng/mL; HR=0.393; P<0.001). Conclusions: This large multi-center retrospective study showed that the objective response was 9.8%, and the proportion of long-term survivors was 15.3% in Korean patients. The prognostic factors predicting long-term survival after sorafenib treatment were hand foot skin reaction, metformin use, concomittent treatment, good liver function, absence of extrahepatic metastasis, low degree of portal vein thrombosis, and low AFP.